SCYNEXIS Announces Four Posters Presented at ASM Microbe 2020 Highlighting the Potential Clinical Utility of Ibrexafungerp

JERSEY CITY, N.J., July 22, 2020 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of four posters at the American Society for Microbiology (ASM) Microbe 2020 held virtually from June through August. The posters, presented as part of the ASM Microbe Online 2020 Summer of Science program, now available online, highlight the potential clinical utility of ibrexafungerp. Ibrexafungerp is the first representative of a new class of antifungal agents called triterpenoids, which are broad-spectrum, fungicidal, and designated by the suffix “-fungerp”. Following the successful completion of its VANISH Phase 3 program, the Company plans to submit a new drug application (NDA) for ibrexafungerp as a treatment for vaginal yeast infections in the second half of this year, while advancing several late-stage programs for the treatment of life-threatening fungal infections in hospitalized patients.
“Fungal infections are increasingly common and often represent serious public health threats, yet there are limited treatment options. The clinical and preclinical studies presented at ASM Microbe 2020 highlight ibrexafungerp’s potential across a broad spectrum of fungal infections, including resistant strains,” said Marco Taglietti, M.D., Chief Executive Officer of SCYNEXIS. “As superbugs flourish and antifungal drug development dwindles, we remain committed to advancing ibrexafungerp, our novel antifungal, for patients in the hospital and community settings. The COVID-19 pandemic is a powerful reminder about the importance of continuous development of anti-infectives.”Poster Details:


All posters will be available on the SCYNEXIS website in the near future via link.About Ibrexafungerp
Ibrexafungerp [pronounced eye-BREX-ah-FUN-jerp] is an investigational antifungal agent and the first representative of a new class of antifungal agents called triterpenoids, which are broad-spectrum, fungicidal, and designated by the suffix “-fungerp”. This agent combines the well-established activity of glucan synthase inhibitors with the potential flexibility of having oral and IV formulations. Ibrexafungerp is currently in development for the treatment of fungal infections caused primarily by Candida (including C. auris) and Aspergillus species. It has demonstrated broad spectrum antifungal activity, in vitro and in vivo, against multidrug-resistant pathogens, including azole- and echinocandin-resistant strains. The FDA has granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for the formulations of ibrexafungerp for the indications of invasive candidiasis (IC) (including candidemia), invasive aspergillosis (IA) and vulvovaginal candidiasis (VVC) and has granted Orphan Drug Designation for the IC and IA indications. Ibrexafungerp is formerly known as SCY-078.About SCYNEXIS
SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. Our lead candidate, ibrexafungerp (formerly known as SCY-078), is a broad-spectrum, IV/oral antifungal agent representing a novel therapeutic class, in late stage development for multiple indications, ranging from vaginal yeast infections to life-threatening fungal infections in hospitalized patients. The SCYNEXIS team has deep expertise in anti-infective drug development and marketing, which can be leveraged to advance ibrexafungerp from clinical development to commercialization. For more information, visit www.scynexis.com.Forward Looking Statement
Statements contained in this press release regarding expected future events or results are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited, to: risks inherent in SCYNEXIS’ ability to successfully develop and obtain FDA approval for ibrexafungerp; the expected costs of studies and when they might begin or be concluded; and SCYNEXIS’ reliance on third parties to conduct SCYNEXIS’ clinical studies. These and other risks are described more fully in SCYNEXIS’ filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K under the caption “Risk Factors” and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.CONTACT: 
Investor Relations
Irina Koffler
Managing Director
LifeSci Advisors, LLC
646-970-4681 (w)
ikoffler@lifesciadvisors.comMedia Relations
Gloria Gasaatura
Account Supervisor
LifeSci Communications
646-970-4688
ggasaatura@lifescicomms.com